歌礼制药-B:预计2026年第二季度向FDA提交口服减肥药Asc36新药临床试验申请

美股速递
Feb 11

歌礼制药-B宣布,公司计划于2026年第二季度向美国食品药品监督管理局(FDA)提交其口服片剂Asc36的新药临床试验(IND)申请,该药物拟用于治疗肥胖症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10